Trade Names:Celestone- Syrup 0.6 mg per 5 mLBetnesol (Canada)Betamethasone Sodium Phosphate and Betamethasone Acetate
Trade Names:Celestone Soluspan- Injection 3 mg betamethasone acetate and 3 mg betamethasone sodium phosphate per mL suspensionBetaject (Canada)Betamethasone Valerate
Trade Names:Beta-Val- Cream 0.1%- Lotion 0.1%
Trade Names:Luxiq- Foam 1.2 mg/gBetaderm (Canada)Prevex B (Canada)ratio-Ectosone (Canada)Valisone Scalp Lotion (Canada)Betamethasone Dipropionate
Trade Names:Betamethasone Dipropionate- Cream 0.05%- Ointment 0.05%
Trade Names:Del-Beta- Lotion 0.05%Diprolene Glycol (Canada)ratio-Topilene (Canada)ratio-Topisone (Canada)Taro-Sone (Canada)Betamethasone Dipropionate, Augmented
Trade Names:Diprolene- Ointment 0.05%- Lotion 0.05%
Trade Names:Diprolene AF- Cream 0.05%
Synthetic, long-acting glucocorticoid that depresses formation, release, and activity of endogenous mediators of inflammation, including prostaglandins, kinins, histamine, liposomal enzymes, and complement system. Also modifies body's immune response.
The t ½ is at least 300 min.
Systemic treatment of primary or secondary adrenal cortex insufficiency, rheumatic disorders, collagen diseases, dermatologic diseases, allergic states, allergic and inflammatory ophthalmic processes, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states (resulting from nephrotic syndrome), GI diseases, multiple sclerosis, tuberculous meningitis and trichinosis with neurologic or myocardial involvement.Topical
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Systemic fungal infections; IM use in idiopathic thrombocytopenic purpura; administration of live virus vaccines when patient is receiving immunosuppressive doses.Topical
Monotherapy in primary bacterial infections. Do not use on face, groin, or axilla or for ophthalmic treatments.
PO 0.6 to 7.2 mg/day.Betamethasone Sodium Phosphate and Betamethasone Acetate
Intrabursal / Intra-articular / Intradermal / Intralesional 0.5 to 9 mg/day, depending on site of administration or condition being treated.Betamethasone Dipropionate, Betamethasone Valerate
Topical Apply sparingly to affected areas 2 to 4 times/day.
Store between 36° and 86°F. Protect from excessive moisture.
May antagonize anticholinesterase effects in myasthenia gravis.Anticoagulants, oral
May alter anticoagulant dose requirements.Barbiturates
May decrease pharmacologic effect of betamethasone.Hydantoins, rifampin
May increase Cl and decrease therapeutic efficacy of betamethasone.Nondepolarizing muscle relaxants (eg, tubocurarine)
May potentiate or counteract neuromuscular blocking action.Salicylates
May reduce serum levels and efficacy of salicylates.Troleandomycin
May increase effects of betamethasone.
Increased urine glucose and serum cholesterol; decreased serum levels of potassium, T 3 , and T 4 ; decreased uptake of I 131 ; false-negative nitroblue-tetrazolium test.
Thromboembolism or fat embolism; thrombophlebitis; necrotizing angiitis; cardiac arrhythmias or ECG changes; syncopal episodes; hypertension; myocardial rupture; CHF.
Convulsions; increased intracranial pressure with papilledema (pseudotumor cerebri); vertigo; headache; neuritis/paresthesias; psychosis; fatigue; insomnia.
Impaired wound healing; thin, fragile skin; petechiae and ecchymoses; erythema; lupus erythematosus–like lesions; suppression of skin test reactions; subcutaneous fat atrophy; purpura; striae; hirsutism; acneiform eruptions; allergic dermatitis; urticaria; angioneurotic edema; perineal irritation; hyperpigmentation; hypopigmentation. Topical application may cause burning; itching; irritation; erythema; dryness; folliculitis; hypertrichosis; pruritus; perioral dermatitis; allergic contact dermatitis; numbness of fingers; stinging and cracking/tightening of skin; maceration of skin; secondary infections; skin atrophy; striae; miliaria; telangiectasia.
Posterior subcapsular cataracts; increased IOP, glaucoma; exophthalmos.
Pancreatitis; abdominal distension; ulcerative esophagitis; nausea; vomiting; increased appetite and weight gain; peptic ulcer with perforation and hemorrhage; small and large bowel perforation.
Increased or decreased motility and number of spermatozoa.
Sodium and fluid retention; hypokalemia; hypokalemic alkalosis; metabolic alkalosis; hypocalcemia; HPA axis suppression; endocrine abnormalities (eg, menstrual irregularities; cushingoid state; growth suppression in children secondary to adrenocortical and pituitary unresponsiveness; increased sweating; decreased carbohydrate tolerance; hyperglycemia; glycosuria; increased insulin or sulfonylurea requirements in diabetics; manifestations of latent diabetes mellitus; negative nitrogen balance caused by protein catabolism; hirsutism).
Musculoskeletal (eg, weakness; myopathy; tendon rupture; osteoporosis; aseptic necrosis of femoral and humeral heads; spontaneous fractures, including vertebral compression fractures and pathologic fracture of long bones); hypersensitivity, including anaphylactic reactions; aggravation or masking of infections; malaise. Topical use may produce same adverse reactions seen with systemic use.
Category C (topical). Safety not established (systemic).
Excreted in breast milk.
Growth and development of infants and children on prolonged therapy must be monitored, even with topical treatment.
May require lower doses. Consider benefits relative to risks.
Anaphylactoid reactions have occurred rarely.
Prolonged therapy may lead to HPA suppression.
Use with caution in patients with recent MI.
Can cause elevated BP, salt and water retention, and increased potassium and calcium excretion. Dietary salt restriction and potassium supplementation may be necessary.
May be harmful in chronic active hepatitis positive for hepatitis B surface antigen.
May mask signs of infection. May decrease host-defense mechanisms.
Use cautiously in ocular herpes simplex because of possible corneal perforation.
May contribute to peptic ulceration, especially in large doses.
Increased dosage of rapidly acting corticosteroid may be needed before, during, and after stressful situations.
Some products contain sulfites, which may cause allergic-type reactions in susceptible individuals.
Abrupt discontinuation may result in adrenal insufficiency. Use is discontinued gradually, while supplementation is increased during times of stress.
Fever, myalgia, arthralgia, malaise, anorexia, nausea, skin desquamation, orthostatic hypotension, dizziness, fainting, dyspnea, hypoglycemia (acute overdosage); cushingoid changes, moonface, central obesity, striae, hirsutism, acne, ecchymoses, hypertension, osteoporosis, myopathy, sexual dysfunction, diabetes, hyperlipidemia, peptic ulcer, infarction, electrolyte and fluid imbalance (chronic overdosage).
Copyright © 2009 Wolters Kluwer Health.